Managing transplant-eligible NDMM patients
Module 2 focuses on managing transplant-eligible (Te) patients with NDMM, with particular attention to high-risk disease. It covers the 2025 IMS-IMWG definition of high-risk multiple myeloma and the main high-risk subgroups (renal impairment, extramedullary disease and high-risk cytogenetics), and works through induction, ASCT and tandem ASCT, consolidation, maintenance and supportive care. After this module you will be able to evaluate treatment strategies for difficult-to-treat patients, compare single versus tandem ASCT, assess the role of consolidation therapy, and analyse maintenance regimens and optimal treatment duration.
Scientific Expert Panel
Gustav Mathiasen,
Zealand University Hospital Roskilde,
Department of Hematology,
Denmark
Dr. Ville Varmavuo,
hematologist, Senior Medical Officer in Charge of Research and Training,
Kymenlaakson hyvinvointialue,
Finland
Accreditation
Obtain CME points
Clinical cases
Throughout the e-learning challenging clinical cases from daily practice are being presented by the International Expert Panel.
